Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Artrolasi; Copper zinc SOD; Cu/Zn-superoxide dismutase; Interceptor; Ontosein; Orgo-M; Ormetein; Peroxinorm; Serosod; Superoxide dismutase - GT Biopharma

Latest Information Update: 10 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OXIS International
  • Developer Tedec Meiji
  • Class Anti-inflammatories; Antirheumatics; Metalloproteins; Radioprotectives
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cystitis; Radiation injuries; Rheumatic disorders
  • Discontinued Reperfusion injury

Most Recent Events

  • 07 Aug 2017 Oxis International is now called GT Biopharma
  • 31 Mar 2011 Orgotein is available for licensing as of 31 Mar 2011. www.oxis.com
  • 22 Mar 2004 OXIS International has been acquired by Axonyx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top